FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386537527> ?p ?o ?g. }

• W4386537527 endingPage "ii21" @default.
• W4386537527 startingPage "ii20" @default.
• W4386537527 abstract "Abstract BACKGROUND The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib has radio and chemosensitizing effects in preclinical models and penetrates GBM in patients at radiosensitizing concentrations. PARP inhibitors sensitize proliferating cells to temozolomide (TMZ) but exacerbate haematological toxicity. Patients with MGMT unmethylated tumours do not benefit from TMZ so it can be withheld, enabling continuous olaparib dosing with radiotherapy (RT). Patients with MGMT methylated tumours benefit from TMZ so olaparib must be combined with chemoradiation (CRT) in an intermittent, low-dose manner. PARADIGM-2 is a clinical trial comprising two parallel phase I studies of olaparib/RT or olaparib/RT/TMZ in newly diagnosed GBM patients stratified by MGMT status. MATERIAL AND METHODS GBM patients aged &lt;70 with WHO performance status 0-1 were eligible. Tumour tissue underwent central pyrosequencing testing for MGMT promoter methylation. MGMT unmethylated patients received daily oral olaparib throughout RT (60 Gray in 30#) and for four weeks afterwards. MGMT methylated patients received intermittent olaparib during CRT (60 Gray plus TMZ 75mg/m2 daily) and for four weeks after. In both arms, olaparib dose was escalated in a 3 + 3 cohort design. ISRCTN 51253312. RESULTS By January 2023, 24 MGMT methylated patients and 43 MGMT unmethylated patients had been recruited. Dose escalation in MGMT unmethylated patients was completed with no dose-limiting toxicities and the recommended phase II dose (RP2D) of olaparib was established at 300 mg twice daily (the full single agent dose). Maximum tolerated dose was not reached. The RP2D cohort was expanded to 30 patients of whom one was excluded because the diagnosis was revised to anaplastic oligodendroglioma. Median overall survival (OS) of the 42 eligible patients was 14.1 months (80% confidence intervals (CI) 12.2 - 15.9), with 12- and 24-month OS estimates of 64.3% (54.0-72.9) and 16.7% (10.1-24.7) respectively. In the dose expansion cohort, 6 of 29 patients are alive with median follow-up time of 22.9 months. Median OS is 14.2 months (12.2-16.9); 12- and 24-month OS estimates are 69.0% (56.5-78.5) and 24.1% (14.8-34.8) respectively. Updated survival data will be presented at the conference. Dose escalation in MGMT methylated patients continues with the current cohort receiving olaparib 150 mg daily 4 days per week. CONCLUSION Pre-treatment stratification by MGMT status in a phase I study in GBM is feasible and enables optimisation of olaparib dosing and scheduling with RT and TMZ. In MGMT unmethylated patients, olaparib can be combined with RT at the full single agent dose (300 mg twice daily) if TMZ is withheld. Of 29 patients receiving this dose, a quarter have survived more than 2 years. In MGMT methylated patients, olaparib can be safely combined with radical CRT when given at lower doses on an intermittent basis (currently 150 mg four days per week)." @default.
• W4386537527 created "2023-09-09" @default.
• W4386537527 creator A5005950432 @default.
• W4386537527 creator A5015933098 @default.
• W4386537527 creator A5025026140 @default.
• W4386537527 creator A5036598776 @default.
• W4386537527 creator A5041442130 @default.
• W4386537527 creator A5045766318 @default.
• W4386537527 creator A5048940397 @default.
• W4386537527 creator A5056093407 @default.
• W4386537527 creator A5063298790 @default.
• W4386537527 creator A5070984695 @default.
• W4386537527 creator A5071407258 @default.
• W4386537527 creator A5080065000 @default.
• W4386537527 creator A5084963696 @default.
• W4386537527 creator A5090229657 @default.
• W4386537527 date "2023-09-01" @default.
• W4386537527 modified "2023-10-16" @default.
• W4386537527 title "OS09.3.A FINAL RESULTS OF THE MGMT UNMETHYLATED ARM OF PARADIGM-2: A PHASE I STUDY OF OLAPARIB AND RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)" @default.
• W4386537527 doi "https://doi.org/10.1093/neuonc/noad137.060" @default.
• W4386537527 hasPublicationYear "2023" @default.
• W4386537527 type Work @default.
• W4386537527 citedByCount "0" @default.
• W4386537527 crossrefType "journal-article" @default.
• W4386537527 hasAuthorship W4386537527A5005950432 @default.
• W4386537527 hasAuthorship W4386537527A5015933098 @default.
• W4386537527 hasAuthorship W4386537527A5025026140 @default.
• W4386537527 hasAuthorship W4386537527A5036598776 @default.
• W4386537527 hasAuthorship W4386537527A5041442130 @default.
• W4386537527 hasAuthorship W4386537527A5045766318 @default.
• W4386537527 hasAuthorship W4386537527A5048940397 @default.
• W4386537527 hasAuthorship W4386537527A5056093407 @default.
• W4386537527 hasAuthorship W4386537527A5063298790 @default.
• W4386537527 hasAuthorship W4386537527A5070984695 @default.
• W4386537527 hasAuthorship W4386537527A5071407258 @default.
• W4386537527 hasAuthorship W4386537527A5080065000 @default.
• W4386537527 hasAuthorship W4386537527A5084963696 @default.
• W4386537527 hasAuthorship W4386537527A5090229657 @default.
• W4386537527 hasConcept C104317684 @default.
• W4386537527 hasConcept C126322002 @default.
• W4386537527 hasConcept C143998085 @default.
• W4386537527 hasConcept C182979987 @default.
• W4386537527 hasConcept C2777389519 @default.
• W4386537527 hasConcept C2779138821 @default.
• W4386537527 hasConcept C2779962180 @default.
• W4386537527 hasConcept C509974204 @default.
• W4386537527 hasConcept C55493867 @default.
• W4386537527 hasConcept C71924100 @default.
• W4386537527 hasConcept C82381507 @default.
• W4386537527 hasConcept C86803240 @default.
• W4386537527 hasConceptScore W4386537527C104317684 @default.
• W4386537527 hasConceptScore W4386537527C126322002 @default.
• W4386537527 hasConceptScore W4386537527C143998085 @default.
• W4386537527 hasConceptScore W4386537527C182979987 @default.
• W4386537527 hasConceptScore W4386537527C2777389519 @default.
• W4386537527 hasConceptScore W4386537527C2779138821 @default.
• W4386537527 hasConceptScore W4386537527C2779962180 @default.
• W4386537527 hasConceptScore W4386537527C509974204 @default.
• W4386537527 hasConceptScore W4386537527C55493867 @default.
• W4386537527 hasConceptScore W4386537527C71924100 @default.
• W4386537527 hasConceptScore W4386537527C82381507 @default.
• W4386537527 hasConceptScore W4386537527C86803240 @default.
• W4386537527 hasIssue "Supplement_2" @default.
• W4386537527 hasLocation W43865375271 @default.
• W4386537527 hasOpenAccess W4386537527 @default.
• W4386537527 hasPrimaryLocation W43865375271 @default.
• W4386537527 hasRelatedWork W2003243316 @default.
• W4386537527 hasRelatedWork W2048098856 @default.
• W4386537527 hasRelatedWork W2055183302 @default.
• W4386537527 hasRelatedWork W2969952426 @default.
• W4386537527 hasRelatedWork W3001769037 @default.
• W4386537527 hasRelatedWork W3018583760 @default.
• W4386537527 hasRelatedWork W3113016627 @default.
• W4386537527 hasRelatedWork W3175416687 @default.
• W4386537527 hasRelatedWork W4286296881 @default.
• W4386537527 hasRelatedWork W4362495302 @default.
• W4386537527 hasVolume "25" @default.
• W4386537527 isParatext "false" @default.
• W4386537527 isRetracted "false" @default.
• W4386537527 workType "article" @default.